Tricuspid Regurgitation
Conditions
Brief summary
The present clinical trial is performed to evaluate the effectiveness and safety of transcatheter tricuspid annuloplasty system manufactured by Shanghai Huihe Healthcare technology Co.,Ltd. for the treatment of subjects with severe or worse tricuspid regurgitation.
Interventions
Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
Sponsors
Shanghai Huihe Medical Technology Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥60, male or female; 2. patients with severe or above secondary tricuspid regurgitation (TR≥4+) (secondary tricuspid regurgitation: tricuspid regurgitation caused by right atrial lesions, right ventricular cardiomyopathy, right ventricular myocardial infarction, left ventricular valvular disease, congenital heart disease and other diseases); 3. A multidisciplinary cardiac team (at least 2 doctors) consisting of cardiovascular physicians, cardiovascular surgeons, radiologists, anesthesiologists, etc., considered the subject to be at high risk for surgery and expected to benefit from tricuspid valve repair; 4. Left ventricular ejection fraction LVEF≥40%; 5. The subject voluntarily participates in the clinical trial and agrees or his/her guardian agrees to sign the informed consent. 6. Tricuspid regurgitation symptoms, such as chest tightness, asthma, shortness of breath, lower limb edema, ascites; 7. NYHA grade 2 to 4; 8. Patients who received tricuspid valve optimal drug therapy for ≥ 30 days were in stable condition; 9. In the case of the following diseases: mitral regurgitation, atrial fibrillation, coronary disease and heart failure, drug treatment should be ≥ 30 days or ≥ 30 days after instrumental treatment and the patient's condition is stable.
Exclusion criteria
1. patients with primary tricuspid regurgitation; 2. Patients with systolic pulmonary artery pressure ≥55 mmHg; 3. Patients with tricuspid valve or annuloplasty or tricuspid related procedure; 4. Patients with posterior tricuspid annulus calcification; 5. Evidence of mass, thrombosis or vegetations in the heart, jugular vein and superior vena cava; 6. patients with moderate or higher aortic stenosis, mitral stenosis, aortic regurgitation or mitral regurgitation; 7. patients with severely uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg); 8. Percutaneous coronary intervention within 1 month; 9. myocardial infarction or known unstable angina within 1 month; 10. Cerebrovascular accident within the past 3 months; 11. patients with active endocarditis or active rheumatic heart disease; 12. Patients with coagulation dysfunction, hypercoagulability or anemia (hemoglobin \< 90 g/L); 13. patients with acute infection or other severe infection; 14. Patients with active peptic ulcer or active gastrointestinal bleeding; 15. severe end-stage diseases (such as malignant tumor, severe lung disease, liver disease, renal failure) with a life expectancy of less than one year; 16. Patients with known allergies or contraindications to the raw materials or drugs (such as antiplatelet drugs and anticoagulants) of the test products; 17. Persons addicted to alcohol, drugs or drugs; 18. Patients with cognitive impairment; 19. patients with histories of epilepsy or mental illness; 20. Participate in any other clinical trial (other than a registry study) within 30 days prior to signing the informed consent; 21. have a previous implantation of a pacemaker or defibrillator, or plan to implant a pacemaker or defibrillator; 22. Tricuspid stenosis; 23. Ebstain syndrome; 24. The anatomy of tricuspid annulus could not be assessed by TEE and TTE; 25. Hemodynamic instability; 26. chronic dialysis patients; 27. women who are pregnant during pregnancy, breast-feeding or during the clinical study; 28. Other conditions that the investigator considers inappropriate for participation in the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality | 1-year after operation | — |
| Change of Tricuspid Regurgitation Grade | 1-year after operation | Change of Tricuspid Regurgitation Grade assessed by corelab than baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| NYHA | 1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years | — |
| The success rate of post operation 12 months | 2 years, 3years, 4 years, 5 years | — |
| 6 minutes walk distance | 1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years | — |
| Change in echocardiographic parameters | 1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years | Change in echocardiographic parameters：Tricuspid annulus A-P diameter（mm）、 Tricuspid annulus perimeter（mm）、Tricuspid annulus area(cm2)、Vena contracta width（mm）、EROA(cm2)、Regurgitation volume(ml)、IVC(mm)。 |
| Change of Tricuspid Regurgitation Grade | 1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years | — |
| Success rate of device implantation | intra-procedure | — |
| Kansas City Cardiomyopathy Questionnaire (KCCQ) | 1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years | — |
Outcome results
None listed